Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Vet Pathol ; 52(6): 998-1011, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26077782

ABSTRACT

Malaria remains one of the most significant public health concerns in the world today. Approximately half the human population is at risk for infection, with children and pregnant women being most vulnerable. More than 90% of the total human malaria burden, which numbers in excess of 200 million annually, is due to Plasmodium falciparum. Lack of an effective vaccine and a dwindling stockpile of antimalarial drugs due to increased plasmodial resistance underscore the critical need for valid animal models. Plasmodium coatneyi was described in Southeast Asia 50 years ago. This plasmodium of nonhuman primates has been used sporadically as a model for severe malaria, as it mimics many of the pathophysiologic features of human disease. This review covers the reported macroscopic, microscopic, ultrastructural, and molecular pathology of P. coatneyi infection in macaques, specifically focusing on the rhesus macaque, as well as describing the critical needs still outstanding in the validation of this crucial model of human disease.


Subject(s)
Disease Models, Animal , Macaca mulatta , Malaria/pathology , Plasmodium/cytology , Animals , Child , Female , Humans , Malaria/parasitology , Pregnancy
2.
Vaccine ; 28(2): 452-62, 2009 Dec 11.
Article in English | MEDLINE | ID: mdl-19857448

ABSTRACT

In an effort to broaden the immune response induced by the RTS,S/AS02(A),vaccine, we have evaluated the immunogenicity of the RTS,S antigen when combined with MSP1(42) and with AMA1, antigens derived from the asexual blood stage. The objectives of this study were (i) to determine whether MSP1(42) and AMA1 vaccines formulated with the AS02(A) Adjuvant System were safe and immunogenic in the rhesus monkey model; (ii) to investigate whether MSP1(42) or AMA1 induced immune interference to each other, or to RTS,S, when added singly or in combinations at a single injection site; (iii) in the event of immune interference, to determine if this could be reduced when antigens were administered at separate sites. We found that MSP1(42) and AMA1 were safe and immunogenic, eliciting antibodies, and Th1 and Th2 responses using IFN-gamma and IL-5 as markers. When malaria antigens were delivered together in one formulation, MSP1(42) and RTS,S reduced AMA1-specific antibody responses as measured by ELISA however, only MSP1(42) lowered parasite growth inhibitory activity of anti-AMA1 antibodies as measured by in vitro growth inhibition assay. Unlike RTS,S, MSP1(42) significantly reduced AMA1 IFN-gamma and IL-5 responses. MSP1(42) suppression of AMA1 IFN-gamma responses was not seen in animals receiving RTS,S+AMA1+MSP1(42) suggesting that RTS,S restored IFN-gamma responses. Conversely, AMA1 had no effect on MSP1(42) antibody and IFN-gamma and IL-5 responses. Neither AMA1 alone or combined with MSP1(42) affected RTS,S antibody or IFN-gamma and IL-5 responses. Immune interference by MSP1(42) on AMA1 antibody responses was also evident when AMA1, MSP1(42) and RTS,S were administered concurrently at separate sites. These results suggest that immune interference may be complex and should be considered for the design of multi-antigen, multi-stage vaccines against malaria.


Subject(s)
Antigens, Protozoan/immunology , Macaca mulatta/immunology , Malaria Vaccines/immunology , Membrane Proteins/immunology , Merozoite Surface Protein 1/immunology , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , Animals , Malaria Vaccines/adverse effects , Merozoite Surface Protein 1/adverse effects
3.
Infect Immun ; 76(1): 229-38, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17954725

ABSTRACT

Several lines of evidence suggest that targeting pre-erythrocytic-stage parasites for malaria vaccine development can provide sterile immunity. The objectives of this study were (i) to evaluate preclinically the safety and immunogenicity of a new recombinant pre-erythrocytic-stage antigen, liver-stage antigen 1 (LSA1), in nonhuman primates; and (ii) to investigate the potential for immune interference between LSA1 and the leading malaria vaccine candidate, RTS,S, by comparing the immune responses after single-antigen vaccination to responses after simultaneous administration of both antigens at separate sites. Using a rhesus monkey model, we found that LSA1 formulated with the GlaxoSmithKline proprietary adjuvant system AS01B (LSA1/AS01B) was safe and immunogenic, inducing high titers of antigen-specific antibody and CD4+ T-cell responses, as monitored by the production of interleukin-2 and gamma interferon, using intracellular cytokine staining. RTS,S/AS01B vaccination was well tolerated and demonstrated robust antibody and moderate CD4+ T-cell responses to circumsporozoite protein (CSP) and HBsAg. Positive CD8+ T-cell responses to HBsAg were detected, whereas the responses to CSP and LSA1 were negligible. For both LSA1/AS01B and RTS,S/AS01B, no statistically significant differences were observed between individual and concurrent administration in the magnitude or duration of antibody and T-cell responses. Our results revealed that both pre-erythrocytic-stage antigens were safe and immunogenic, administered either separately or simultaneously to rhesus monkeys, and that no significant immune cross interference occurred with concurrent separate-site administration. The comparison of the profiles of immune responses induced by separate-site and single-site vaccinations with LSA1 and RTS,S warrants further investigation.


Subject(s)
Adjuvants, Immunologic/pharmacology , Antigens, Protozoan/immunology , Lipid A/analogs & derivatives , Macaca mulatta/immunology , Malaria Vaccines/immunology , Malaria, Falciparum/prevention & control , Plasmodium falciparum/immunology , Saponins/pharmacology , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Protozoan/blood , Antigens, Protozoan/administration & dosage , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Cytokines/metabolism , Lipid A/administration & dosage , Lipid A/pharmacology , Malaria Vaccines/administration & dosage , Malaria Vaccines/adverse effects , Saponins/administration & dosage , Time Factors
4.
Antimicrob Agents Chemother ; 50(12): 4132-43, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16966402

ABSTRACT

Mefloquine has been one of the more valuable antimalarial drugs but has never reached its full clinical potential due to concerns about its neurologic side effects, its greater expense than that of other antimalarials, and the emergence of resistance. The commercial development of mefloquine superseded that of another quinolinyl methanol, WR030090, which was used as an experimental antimalarial drug by the U.S. Army in the 1970s. We evaluated a series of related 2-phenyl-substituted alkylaminoquinolinyl methanols (AAQMs) for their potential as mefloquine replacement drugs based on a series of appropriate in vitro and in vivo efficacy and toxicology screens and the theoretical cost of goods. Generally, the AAQMs were less neurotoxic and exhibited greater antimalarial potency, and they are potentially cheaper than mefloquine, but they showed poorer metabolic stability and pharmacokinetics and the potential for phototoxicity. These differences in physiochemical and biological properties are attributable to the "opening" of the piperidine ring of the 4-position side chain. Modification of the most promising compound, WR069878, by substitution of an appropriate N functionality at the 4 position, optimization of quinoline ring substituents at the 6 and 7 positions, and deconjugation of quinoline and phenyl ring systems is anticipated to yield a valuable new antimalarial drug.


Subject(s)
Antimalarials/pharmacology , Mefloquine/analogs & derivatives , Mefloquine/pharmacology , 3T3 Cells , Animals , Antimalarials/chemical synthesis , Antimalarials/chemistry , Antimalarials/economics , Antimalarials/metabolism , Antimalarials/pharmacokinetics , Antimalarials/toxicity , Aotidae , Computer Simulation , Drug Evaluation, Preclinical , Erythrocytes/parasitology , Female , Hydrogen-Ion Concentration , Inhibitory Concentration 50 , Male , Mefloquine/chemical synthesis , Mefloquine/chemistry , Mefloquine/economics , Mefloquine/metabolism , Mefloquine/pharmacokinetics , Mefloquine/toxicity , Mice , Microscopy, Confocal , Molecular Structure , Neurons/drug effects , Neurons/metabolism , Parasitemia/drug therapy , Plasmodium berghei/drug effects , Plasmodium falciparum/drug effects , Plasmodium vivax/drug effects , Solubility , Structure-Activity Relationship
5.
Antimicrob Agents Chemother ; 49(11): 4508-14, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16251289

ABSTRACT

Dengue fever and dengue hemorrhagic fever are caused by infection with any one of the four dengue viruses (DVs) and are significant public health burdens throughout the tropics. Higher viremia levels are associated with greater dengue disease severity. A therapeutic intervention to suppress viremia early in DV infection could potentially ameliorate severe disease. Recombinant alpha interferon 2a (rIFN-alpha-2a, Roferon-A) suppressed DV replication in human peripheral blood mononuclear cells in vitro. We therefore examined the effects of rIFN-alpha-2a and pegylated recombinant IFN-alpha-2a (PEG-rIFN-alpha-2a, PEGASYS) on DV serotype 2 (DV-2) viremia in rhesus monkeys. Flavivirus-naïve monkeys were inoculated with DV-2 and randomized to receive a single dose of rIFN-alpha-2a (10 million international units/m2) versus placebo or PEG-rIFN-alpha-2a (6 microg/kg) versus placebo 1 day after the onset of viremia. Serial daily viremia levels were measured, and convalescent-phase DV-2 neutralizing antibody titers were determined. Compared to placebo, a single injection of rIFN-alpha-2a temporarily suppressed DV-2 replication and delayed the time to peak viremia by a median of 3 days. However, measures of total viral burden were not different between the two groups. A single injection of PEG-rIFN-alpha-2a significantly lowered daily viremia levels and improved virus clearance, starting 48 h after administration. There were no significant differences in DV-2 neutralizing antibody titers between the treatment and placebo groups at 30 and 90 days postinfection. Based on their individual effects, future studies should investigate a combination of rIFN-alpha-2a and PEG-rIFN-alpha-2a for suppression of dengue virus viremia and as a potential therapeutic intervention.


Subject(s)
Antiviral Agents/therapeutic use , Dengue/drug therapy , Disease Models, Animal , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Viremia/drug therapy , Animals , Antibodies, Viral/blood , Dengue Virus/drug effects , Dengue Virus/immunology , Dengue Virus/physiology , Interferon alpha-2 , Macaca mulatta , Neutralization Tests , Recombinant Proteins , Virus Replication/drug effects
6.
Am J Trop Med Hyg ; 66(5): 516-25, 2002 May.
Article in English | MEDLINE | ID: mdl-12201585

ABSTRACT

The neurotoxicity of beta-arteether (AE) is related to drug accumulation in blood due to slow and prolonged absorption from the intramuscular injection sites. In this efficacy and toxicity study of AE, the traditional sesame oil vehicle was replaced with cremophore to decrease the accumulation and toxicity of AE. Dihydroartemisinin (DQHS), a more toxic and active metabolite of AE, was also analyzed. When administered at a daily dosage of 25 mg/kg for seven days, blood accumulation of AE with sesame oil (AESO) was used had a 7.5-fold higher area under the curve (AUC) (on last versus first day dosing), while AE with cremophore (AECM) had only a 1.8-fold higher AUC. Although the accumulation of AECM was greatly reduced, its total exposure level (46.29 microg x h/ml) was 2.7-fold higher than with AESO (16.92 microg x h/ml) due to a higher bioavailability of AECM (74.5%) compared with AESO (20.3%). Total exposure time (calculated at over the minimal detected neurotoxicity level of 41.32 ng/ml) of AECM was 103 hours during the whole treatment period (192 hours), which was more than one-third (37%) less than with AESO (162 hours). Similar pharmacokinetic results were also shown with the active metabolite, DQHS. Anorexia and gastrointestinal toxicity with AESO were significantly more severe than with AECM (P < 0.001). Histopathologic examination of the brain demonstrated neurotoxic changes; the AESO rat group was significantly more severe than the AECM rat group. The brain injury scores with AECM were mild to moderate (2.3-3.0), and with AESO they were moderate to severe (3.0-4.7) on day 7 and day 10, respectively. In addition, the results of a 50% cure dose (CD50) against Plasmodium berghei in mice were 34.1 mg/kg for AESO and 14.2 mg/kg for AECM, indicating a significant higher efficacy was found in the AECM animals. Toxicity and efficacy of DQHS were also dependent on its exposure time and level, which was the same as its parent drug (AE). In conclusion, following the seven-day treatment in rats, AE and DQHS exposure time and level varied based on the vehicle used. The extension of drug exposure time and the low peak level of AE and DQHS were more associated with severe neurotoxicity and lower antimalarial efficacy, whereas the high level and short exposure time of AE and DQHS resulted in higher efficacy and milder toxicity.


Subject(s)
Anorexia/chemically induced , Antimalarials/toxicity , Artemisinins , Malaria/drug therapy , Neurotoxins/toxicity , Sesquiterpenes/toxicity , Sesquiterpenes/therapeutic use , Animals , Antimalarials/pharmacokinetics , Antimalarials/therapeutic use , Area Under Curve , Artemether , Biological Availability , Male , Mice , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Neurotoxins/pharmacokinetics , Plasmodium berghei/drug effects , Rats , Rats, Sprague-Dawley , Sesquiterpenes/pharmacokinetics , Tissue Distribution
7.
J Immunol Methods ; 252(1-2): 15-23, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11334961

ABSTRACT

Recognition of dendritic cells (DCs) as initiators and modulators of immune responses and growing use of rhesus monkeys for the preclinical optimization of vaccine formulations prompted characterization of the phenotype and function of isolated rhesus peripheral blood DCs. We developed a flow cytometric method to directly identify and isolate DCs from rhesus peripheral blood whereby a T cell depleted population negative for CD3, CD14, CD16 and CD20 but positive for CD83 yielded a cell population with surface markers, morphology, and a cytokine profile similar to human myeloid DCs. Rhesus blood DCs were more effective than monocytes and B cells in mixed lymphocyte reactions and in the presentation of recombinant malaria blood stage antigen MSP-1((42)) to autologous T cells. The ability to isolate rhesus blood DC from peripheral blood should be a useful tool for immunological investigations.


Subject(s)
Cell Separation/methods , Dendritic Cells , Flow Cytometry/methods , Animals , Antigen Presentation/immunology , Antigens, CD , Dendritic Cells/classification , Dendritic Cells/cytology , Dendritic Cells/drug effects , Dendritic Cells/immunology , Flow Cytometry/statistics & numerical data , Humans , Immunoglobulins/immunology , Immunophenotyping , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/immunology , Lymphocyte Culture Test, Mixed , Macaca mulatta , Membrane Glycoproteins/immunology , Merozoite Surface Protein 1/immunology , T-Lymphocytes/immunology , CD83 Antigen
8.
Anat Embryol (Berl) ; 201(5): 383-97, 2000 May.
Article in English | MEDLINE | ID: mdl-10839633

ABSTRACT

Malaria poses a threat across several continents: Eurasia (Asia and parts of Eastern Europe), Africa, Central and South America. Bradley (1991) estimates human exposure at 2,073,000,000 with infection rates at 270,000,000, illnesses at 110,000,000, and deaths at 1,000,000. Significant mortality rates are attributed to infection by the parasite Plasmodium falciparum, with an estimated 90% among African children. A worldwide effort is ongoing to chemically and pharmacologically characterize a class of artemisinin compounds that might be promising antimalarial drugs. The U.S. Army is studying the efficacy and toxicity of several artemisinin semi-synthetic compounds: arteether, artemether, artelinic acid, and artesunate. The World Health Organization and the U.S. Army selected arteether for drug development and possible use in the emergency therapy of acute, severe malaria. Male Rhesus monkeys (Macaca mulatta) were administered different daily doses of arteether, or the vehicle alone (sesame oil), for a period of either 14 days, or 7 days. Neuropathological lesions were found in 14-day arteether treated monkeys in the precerebellar nuclei of the medulla oblongata, namely: (1) the lateral reticular nuclei (subnuclei magnocellularis, parvicellularis, and subtrigeminalis), (2) the paramedian reticular nuclei (subnuclei accessorius, dorsalis, and ventralis), and the perihypoglossal nuclei (n. intercalatus of Staderini, n. of Roller, n. prepositus hypoglossi). The data demonstrate that the simina meduallry precerebellar nuclei have a high degree of vulnerability when arteether is given for 14 days at dose levels between 8mg/kg per day and 24 mg/kg per day. The neurological consequences of this treatment regimen could profoundly impair posture, gait, and autonomic regulation, while eye movement disorders might also be anticipated.


Subject(s)
Antimalarials/toxicity , Artemisinins , Brain Injuries/chemically induced , Brain Injuries/pathology , Cerebellum/drug effects , Cerebellum/pathology , Medulla Oblongata/drug effects , Medulla Oblongata/pathology , Neural Pathways/drug effects , Neural Pathways/pathology , Reticular Formation/drug effects , Reticular Formation/pathology , Sesquiterpenes/toxicity , Animals , Brain Injuries/physiopathology , Brain Mapping , Cerebellum/physiopathology , Dose-Response Relationship, Drug , Drug Administration Schedule , Macaca mulatta , Malaria, Cerebral/drug therapy , Male , Medulla Oblongata/physiopathology , Nerve Degeneration/chemically induced , Nerve Degeneration/pathology , Nerve Degeneration/physiopathology , Neural Pathways/physiopathology , Neurons/drug effects , Neurons/pathology , Reticular Formation/physiopathology
9.
Am J Trop Med Hyg ; 60(3): 329-37, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10466957

ABSTRACT

Placebo-controlled field efficacy trials of new Japanese encephalitis (JE) vaccines may be impractical. Therefore, an animal model to evaluate efficacy of candidate JE vaccines is sought. Previous work has shown that exposure of monkeys to JE virus (JEV) via the intranasal route results in encephalitis. Here we report the further development of this model and the availability of titered virus stocks to assess the protective efficacy of JE vaccines. To determine the effective dose of our JE challenge virus, dilutions of a stock JEV (KE-93 isolate) were inoculated into four groups of three rhesus monkeys. A dose-dependent response was observed and the 50% effective dose (ED50) was determined to be 6.0 x 10(7) plaque forming units (pfu). Among animals that developed encephalitis, clinical signs occurred 9-14 days postinoculation. Infection with JEV was confirmed by detection of JEV in nervous tissues and IgM to JEV in the cerebrospinal fluid. Viremia with JEV was also detected intermittently throughout infection. Validation of the model was performed using a known effective JE vaccine and saline control. One ED90 of virus (2.0 x 10(9) pfu) was used as a challenge dose. Four of four animals that received saline control developed encephalitis while one of four monkeys administered the JE vaccine did so. This study demonstrates that the virus strain, route of inoculation, dose, and the outcome measure (encephalitis) are suitable for assessment of protective efficacy of candidate JE vaccines.


Subject(s)
Disease Models, Animal , Encephalitis Virus, Japanese/immunology , Encephalitis, Japanese/prevention & control , Macaca mulatta , Viral Vaccines/standards , Administration, Intranasal , Animals , Animals, Suckling , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , DNA Primers/chemistry , DNA, Viral/chemistry , Electrophoresis, Agar Gel , Encephalitis Virus, Japanese/pathogenicity , Encephalitis, Japanese/immunology , Enzyme-Linked Immunosorbent Assay , Female , Hemagglutination Inhibition Tests , Immunization , Male , Mice , Neutralization Tests , RNA, Viral/analysis , RNA, Viral/blood , RNA, Viral/cerebrospinal fluid , Reverse Transcriptase Polymerase Chain Reaction , Viral Vaccines/administration & dosage , Viral Vaccines/immunology , Viremia/cerebrospinal fluid
10.
Am J Trop Med Hyg ; 60(3): 338-42, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10466958

ABSTRACT

Twelve rhesus macaques (Macaca mulatta) challenged intranasally with a wild-type Japanese encephalitis virus (JEV) developed clinical signs 11-14 days later. Tissues from the cerebral cortex, cerebellum, brainstem, thalamus, meninges, and all levels of the spinal cord were stained for JEV antigen with hyperimmune mouse ascitic fluid and streptavidin-alkaline phosphatase; immunofluorescent staining was also done on frozen sections. Viral antigen was found in all cell layers of the cerebellum, the gray matter of the thalamus and brainstem, and the ventral horn of all levels of the spinal cord. Staining was limited to neurons and their processes. Histopathologic changes were limited to the nervous system and characterized by nonsuppurative meningoencephalitis. These results were comparable with those of previous studies done with human autopsy tissues. Intranasal inoculation of rhesus monkeys with JEV was effective in producing clinical disease comparable with natural disease in humans and may serve as a model to evaluate protective efficacy of candidate JEV vaccines.


Subject(s)
Disease Models, Animal , Encephalitis Virus, Japanese/pathogenicity , Encephalitis, Japanese/prevention & control , Macaca mulatta , Administration, Intranasal , Animals , Animals, Suckling , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , Antigens, Viral/analysis , Brain/virology , Encephalitis Virus, Japanese/immunology , Female , Hemagglutination Inhibition Tests , Humans , Immunohistochemistry , Male , Mice , Spinal Cord/virology , Viremia
11.
Am J Trop Med Hyg ; 60(3): 343-9, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10466959

ABSTRACT

Two poxvirus-vectored vaccines for Japanese encephalitis (JE), NYVAC-JEV and ALVAC-JEV, were evaluated in rhesus monkeys for safety, immunogenicity, and protective efficacy. The vaccines were given to four monkeys each on study days 0 and 28 along with saline placebo on day 7. For controls, the licensed BIKEN JE vaccine and a saline placebo were given to other groups of four monkeys on days 0, 7, and 28. No systemic effects were observed. All injection site reactions were mild. All vaccines elicited appreciable JE-specific neutralizing antibody responses. However, a more rapid increase and higher peak level of antibody were seen in the BIKEN group as compared with the NYVAC-JEV and ALVAC-JEV groups. The peak neutralizing antibody level in the NYVAC-JEV group was higher than that of the ALVAC-JEV group. Antibody persisted in all four BIKEN recipients through 273 days of follow-up, whereas, the antibody level decreased to the threshold of detection in two NYVAC-JEV and all four ALVAC-JEV recipients by day 120. On day 273, all monkeys were given a booster dose. A rapid increase in neutralizing antibody was seen in all vaccine recipients by seven days. Two months after the booster dose, all monkeys were challenged intranasally with one 90% effective dose of JE virus. Four recipients of saline, three of ALVAC-JEV, one of NYVAC-JEV, and one of BIKEN experienced encephalitis. This study suggests that the NYVAC-JEV and ALVAC-JEV vaccines are safe and immunogenic in monkeys and that the NYVAC-JEV and BIKEN vaccines are effective in protecting monkeys from encephalitis.


Subject(s)
Encephalitis Virus, Japanese/immunology , Encephalitis, Japanese/prevention & control , Vaccines, Synthetic/standards , Viral Vaccines/standards , Administration, Intranasal , Animals , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , Chick Embryo , Disease Models, Animal , Encephalitis, Japanese/immunology , Enzyme-Linked Immunosorbent Assay , Female , Immunization , Macaca mulatta , Male , Mice , Neutralization Tests , RNA, Viral/blood , RNA, Viral/cerebrospinal fluid , Rabbits , Reverse Transcriptase Polymerase Chain Reaction , Vaccines, Synthetic/immunology , Viral Vaccines/immunology , Viremia
12.
Contemp Top Lab Anim Sci ; 38(1): 76-80, 1999 Jan.
Article in English | MEDLINE | ID: mdl-12086458

ABSTRACT

The lesser bandicoot rat (Bandicota savilei) is a wild field rat commonly found in Thailand. Vaginal smears were obtained from five colony-born animals twice daily for 28 days and stained with Giemsa stain. The external appearance of the vulva and appearance of the tip of vaginal swabs were recorded. All cells, including nucleated or keratinized epithelial cells and leukocytes, were quantified by percentage. No changes of the external genitalia were observed. The gross appearance of the vaginal swab may distinguish estrus and diestrus. Vaginal swabs contained a white or yellow material during estrus or diestrus, respectively. Changes in vaginal cytology at each stage of the estrous cycle of the lesser bandicoot rat were similar to those of the common laboratory rat. Estrus stages of the five rats occurred every 3 or 4 days. One female was introduced to a male after diestrus and produced a litter of six pups 27 days after pairing.

13.
Am J Trop Med Hyg ; 56(4): 390-6, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9158046

ABSTRACT

Male rhesus monkeys (Macaca mulatta) were administered daily doses of the antimalarial drug arteether. The 14-day treated group received either 24 mg/kg/day, 16 mg/kg/day, or 8 mg/kg/day. The seven-day treatment group received either 24 mg/kg/day or 8 mg/kg/day. All control cases in each group received the sesame oil vehicle alone. Neurologic signs were absent for animals in the seven and 14-day treatment groups except for one monkey which showed diffuse piloerection on day 14, and another monkey receiving 24 mg/kg/day for seven days showed mild lethargy after the fourth day. Mild, sporadic anorexia was noted in all animals by day 14, and a single animal showed diffuse piloerection on day 14. Surgical anesthesia preceded killing by exsanguination and was accompanied by perfusion fixation of the central nervous system. Brain sections were cut and then stained for study by light microscopy. Evidence of neuronal pathology, both descriptive and numerical, was collected. The neuroanatomic and neuropathologic findings demonstrated that arteether produced extensive brainstem injury when administered for 14 days. The magnitude of brainstem neurotoxicity was dose-dependent, where injury was greatest at the 24 mg/kg/day dose level, less at the 16 mg/kg/day dose level, and least at the 8 mg/kg/day dose level. Arteether induced multiple systems injury to brainstem nuclei of 1) the reticular formation (cranial and caudal pontine nuclei, and medullary gigantocellular and paragigantocellular nuclei); 2) the vestibular system (medial, descending, superior, and lateral nuclei); and 3) the auditory system (superior olivary nuclear complex and trapezoid nuclear complex). The vestibular nuclei and the reticular formation were most severely injured, with the auditory system affected less. The cranial nerve nuclei (somatic and splanchnic) appeared to escape damage, with the exception of the abducens nerve nucleus. The same brainstem nuclear groups of seven-day treated monkeys appeared normal. The statistical data are concordant with the descriptive data in demonstrating neurotoxic effects. In summary, no neurologic deficits were detected in any of the vehicle control monkeys (14-day and seven-day cases). Monkeys in the 14-day treatment group were free of clinical neurologic signs throughout the first week. At day 14, fine horizontal nystagmus was seen in one monkey, and another monkey exhibited diffuse piloerection. Monkeys in the seven-day treatment group were free of clinical neurologic signs except for one case. This monkey was treated with 24/mg/kg/day of arteether and exhibited lethargy after the fourth day. These indications of dysfunction arose too late to be practical indicators of neurotoxicity.


Subject(s)
Antimalarials/toxicity , Artemisinins , Central Nervous System/drug effects , Macaca mulatta/physiology , Neurons/drug effects , Sesquiterpenes/toxicity , Animals , Central Nervous System/pathology , Cranial Nerves/drug effects , Cranial Nerves/pathology , Disease Models, Animal , Male , Olivary Nucleus/drug effects , Olivary Nucleus/pathology , Reticular Formation/drug effects , Reticular Formation/pathology , Vestibular Nuclei/drug effects , Vestibular Nuclei/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...